Brazil's breast cancer drug market set to grow to $611 million by 2014

The breast cancer drug market in Brazil will grow from $424 million in 2009 to $611 million in 2014, according to a new report from advisory firm Decision Resources. Factors promoting the market's growth include steady increases in the number of incident breast cancer cases, shifts toward higher-cost chemotherapy and hormonal regimens in the adjuvant setting and increases in the use of targeted therapies following novel product launches and label extensions.

"The value of the Brazilian breast cancer drug market in 2009 ($424 million) rivals those in some major pharmaceutical markets (UK, Japan) and greatly exceeds breast cancer drug sales in other emerging markets (China, India, Russia)," stated Decision Resources' therapeutic area director Kate Hohenberg. "A well-established public health care system that pays the cost of drug therapy for eligible patients and a small but lucrative pool of privately insured patients support Brazil's sizeable breast cancer drug market," she added.

New drugs expected to come to Brazil's market